Testing CUE-101 schedules before treatment for HPV16 throat cancer
Part of Cancer clinical trials.
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell cancer in the oropharynx, or a suspicious neck lymph node area where the source is thought to be the oropharynx (levels 2–3).
- Your cancer is stage I–III, but specific early cases (T1N0 and T2N0) are not allowed.
- Your doctor has decided you should get standard treatment: surgery with added therapy, or definitive chemoradiation.
- Your tumor tests positive for HPV16, and a marker called p16 is positive (high level staining).
- You have the HLA-A*02:01 blood marker, confirmed with a specific blood test.
- You are age 18+, able to do normal daily activities fairly well (ECOG 0–1), and your blood/organ tests are within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
This study tests a way to use less radiation for HPV-related throat cancer. Doctors will adjust your treatment based on a simple blood test that tracks cancer DNA, so you may get only the treatment you need.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This trial is testing a surgical approach for people with HPV-related oropharyngeal cancer that is stage I or II (but not the very smallest). The goal is to see if removing the tumor through the mouth and taking out neck lymph nodes is effective and safe. It may be an option if you are healthy enough for surgery.
This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.